The European Union has blocked Illumina’s $7.1 billion acquisition of cancer detection test maker Grail, saying that Illumina failed to address its concerns about the deal restricting competition.
Illumina said immediately it will appeal the ruling, which would force it to unwind the deal that it closed in August last year. At the same time, it added it would consider other strategic alternatives for the unit, in the event that its appeal fails.
Illumina has held Grail, whose technology can screen asymptomatic patients for more than 50 types of cancer, as a separate company while EU’s review played out.
“Illumina can make Grail’s life-saving multi-cancer early detection test more available, more affordable, and more accessible – saving lives and lowering healthcare costs,” general counsel Charles Dadswell said in a statement by the company.
In her ruling, EU Competition Commissioner Margrethe Vestager had taken a very different opinion, echoing the concerns of the U.S. Federal Trade Commission. The FTC has also initiated an administrative review of the deal, despite a ruling from the agency’s chief administrative judge that the merger would not harm competition.
“With this transaction, Illumina would have an incentive to cut off Grail’s rivals from accessing its technology, or otherwise disadvantage them,” Vestager said. “It is vital to preserve competition between early cancer detection test developers at this critical stage of development,” she added, noting that Illumina had failed to put forward any remedies to address the Commission’s concerns.
The Commission deemed Illumina “currently the only credible supplier of a technology allowing to develop and process” the cancer tests that Grail and others are striving to develop.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Allows FTC Antitrust Case Against Amazon to Move Forward
Oct 1, 2024 by
CPI
SAP Leader Urges Caution on EU AI Rules, Warns of Competitive Disadvantage
Oct 1, 2024 by
CPI
Colorado’s Grocery Workers Unite to Oppose $24.6 Billion Supermarket Merge
Oct 1, 2024 by
CPI
Canada’s Competition Bureau Warns Businesses of Tougher Enforcement
Oct 1, 2024 by
CPI
Top Antitrust Lawyers Launch New Boutique Firm
Oct 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh